<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00729859</url>
  </required_header>
  <id_info>
    <org_study_id>33853-A</org_study_id>
    <secondary_id>U54HD042454</secondary_id>
    <nct_id>NCT00729859</nct_id>
  </id_info>
  <brief_title>CEP-1 Hormonal Regulation of Circulating Endothelial Progenitor Cells and HDL-C in Men</brief_title>
  <acronym>CEP-1</acronym>
  <official_title>Hormonal Regulation of Circulating Endothelial Progenitor Cells and HDL-C in Men Title Changed With New Protocol (12/14/09): Hormonal Regulation of HDL-C in Men</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Washington</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Washington</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The original purpose of this research study was to understand the effects of testosterone (T)
      and estrogen on stem cells in the blood. The knowledge would be used to help understand the
      effects of T and estrogen on cardiovascular (heart and blood vessel) disease, and to help in
      the development of a safe male hormonal contraceptive.

      The effect of androgens on the number of circulating endothelial progenitor (CEP) cells would
      best be observed in group 1 (placebo). Upon observation of group 1 under original protocol,
      changes in CEP cells were not significant but there were changes in markers of inflammation,
      lipids, and HDL protein composition. A modification to the protocol and title were made to
      reflect this for groups 2 and 3: Hormonal regulation of HDL-C in Men.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      We will be administering three drugs: testosterone gel (T), anastrozole, and acyline. We want
      to see their effects on stem cells and hormone levels in the blood. Acyline suppress
      luteinizing hormone(LH) and follicle-stimulating hormone(FSH), which are hormones made by the
      pituitary gland, thus blocking the signal from the brain that causes the testes to make
      testosterone. Therefore acyline blocks testosterone production. Some men may experience side
      effects such as hot flashes or irritability from the low levels of T caused by acyline. We
      are studying whether adding T to acyline will reduce or eliminate these side effects.

      Since heart disease is a common problem in men we want to know about the effects of male
      hormonal contraception on the cardiovascular system. One way to evaluate these risks is to
      measure the number of progenitor cells and the types of cholesterol in the blood. Progenitor
      cells are cells that travel in the blood and go to areas of blood vessel injury to help
      repair the damage amd may help prevent heart attacks and stokes. Some studies suggest that T
      administration may increase the number of these cells in the blood but other studies have
      shown that estrogen may be responsible for this effect. In addition, T and estrogen may
      affect the amount and type of HDL cholesterol in the blood. This is the &quot;good&quot; cholesterol
      that is thought to protect people from heart attacks and strokes. Therefore, more studies to
      test the effects of T and estrogen on progenitor cells in the blood and to understand HDL
      cholesterol in men receiving testosterone are needed.

      Acyline is an experimental drug. The FDA allows its use only in research with a small number
      of volunteers. So far, over 125 men have received acyline. Anastrozole is a drug that blocks
      the production of estrogen from testosterone. Anastrozole has been given to men safely in the
      past. Anastrozole is not approved for use in men and is also an experimental drug.
      Testosterone gel will also be used in this study. It is FDA approved for use in men with low
      testosterone levels.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2008</start_date>
  <completion_date type="Actual">May 2010</completion_date>
  <primary_completion_date type="Actual">May 2010</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Endothelial Progenitor Cells</measure>
    <time_frame>Baseline, Day 28</time_frame>
    <description>Number of CD33 + CD134+ cells as a percentage of all lymphocytes</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Follicle Stimulating Hormone (FSH)</measure>
    <time_frame>Baseline, 28 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Luteinizing Hormone Concentration (LH)</measure>
    <time_frame>Baseline, Day 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Testosterone Concentration</measure>
    <time_frame>Baseline, Day 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Estradiol Concentration</measure>
    <time_frame>Baseline, Day 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sex Hormone Binding Globulin (SHBG)</measure>
    <time_frame>Baseline, Day 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quantitative Insulin Sensitivity Check Index (QUICKI)</measure>
    <time_frame>Baseline, Day 28, Day 56</time_frame>
    <description>QUICKI is a measure of insulin sensitivity calculated using fasting insulin and glucose concentration in a participants blood. Higher QUICKI are associated with decreased insulin resistance and increased insulin sensitivity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Homeostasis Model of Insulin Resistance (HOMA-IR)</measure>
    <time_frame>Baseline, Day 28, Day 56</time_frame>
    <description>HOMA IR is a measure of insulin sensitivity calculated using fasting insulin and glucose concentration in a participants blood. Higher HOMA IR numbers are associated with increased insulin resistance and decreased insulin sensitivity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fasting Serum Insulin</measure>
    <time_frame>Baseline, Day 28, Day 56</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fasting Lipid Levels</measure>
    <time_frame>Baseline, Day 28, Day 56</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">31</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Acyline 300 µg/kg injections every two weeks (2 doses) + placebo (no active ingredients) gel daily for 28 days + oral placebo pill daily for 28 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Acyline 300 µg/kg injections every two weeks (2 doses) + Testosterone gel 100 mg daily for 28 days + oral placebo pill daily for 28 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Acyline 300 μg/kg injections every two weeks (2 doses) for 28 days + Testosterone gel 100 mg daily for 28 days + oral anastrozole pill 1 mg daily for 28 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Acyline</intervention_name>
    <description>Acyline 300 μg/kg injections every two weeks (2 doses) for 28 days + placebo Testosterone gel daily for 28 days + placebo oral anastrozole pill daily for 28 days</description>
    <arm_group_label>Group 1</arm_group_label>
    <other_name>placebo testosterone gel</other_name>
    <other_name>placebo pill</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Acyline + Testosterone gel</intervention_name>
    <description>Acyline 300 μg/kg injections every two weeks (2 doses) for 28 days + Testosterone gel 100 mg daily for 28 days + placebo oral pill 1 mg daily for 28 days</description>
    <arm_group_label>Group 2</arm_group_label>
    <other_name>Acyline</other_name>
    <other_name>testosterone gel</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Acyline + testosterone gel + anastrozole</intervention_name>
    <description>Acyline 300 μg/kg injections every two weeks (2 doses) for 28 days + Testosterone gel 100 mg daily for 28 days + oral anastrozole pill 1 mg daily for 28 days</description>
    <arm_group_label>Group 3</arm_group_label>
    <other_name>Acyline</other_name>
    <other_name>Testosterone gel</other_name>
    <other_name>Anastrozole</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Males age 18-55 years

          -  Normal serum total testosterone (300 ng/dl-1000 ng/dl)

          -  Normal LH and FSH levels

          -  Taking no regular medications

          -  Normal baseline serum hematology, chemistry and liver function tests

          -  Agrees not to donate blood during the study

          -  Agrees to use a form of contraception during the study

          -  Subject must be able to comply with all study procedures

        Exclusion Criteria:

          -  Clinically significant screening assessments or other relevant disease, allergy or
             surgery, as revealed by history, physical examination and/or laboratory assessments,
             which may limit participation or prevent completion of the study

          -  History of prostate cancer, breast cancer, or benign prostatic hypertrophy

          -  Prostate-specific antigen (PSA) &gt; 3.0

          -  History of regular, chronic testosterone or anabolic steroid use in the past year

          -  Chronic medical illness, prostate disease, or cardiovascular disease

          -  History of a bleeding disorder or need for anticoagulation

          -  Skin condition that might interfere with or be exacerbated by T gel use

          -  Sitting systolic blood pressure &gt; 180mm Hg or &lt;90 mm Hg or sitting diastolic blood
             pressure &gt;110 mm Hg or &lt; 60 mm Hg.

          -  History of clinically significant, untreated sleep apnea

          -  Participation in another drug-related research study within the past 2 months

          -  Participating in a regular physical relationship with a pregnant woman

          -  History of hypersensitivity to any of the study medications (T gel, anastrozole,
             acyline)

          -  History of medical or surgical therapy for benign prostatic hypertrophy

          -  Hematocrit &gt; 55%

          -  History of drug or alcohol abuse within last 6 months

          -  Abnormal digital rectal exam at screening
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Stephanie Page, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Washington</affiliation>
  </overall_official>
  <removed_countries>
    <country>United States</country>
  </removed_countries>
  <link>
    <url>http://depts.washington.edu/popctr/</url>
    <description>http://depts.washington.edu/popctr/is Dedicated to basic and clinical research focused primarily on the male reproductive system.</description>
  </link>
  <reference>
    <citation>Phillips GB. Is atherosclerotic cardiovascular disease an endocrinological disorder? The estrogen-androgen paradox. J Clin Endocrinol Metab. 2005 May;90(5):2708-11. Epub 2005 Feb 1.</citation>
    <PMID>15687329</PMID>
  </reference>
  <reference>
    <citation>Bebb RA, Anawalt BD, Christensen RB, Paulsen CA, Bremner WJ, Matsumoto AM. Combined administration of levonorgestrel and testosterone induces more rapid and effective suppression of spermatogenesis than testosterone alone: a promising male contraceptive approach. J Clin Endocrinol Metab. 1996 Feb;81(2):757-62.</citation>
    <PMID>8636300</PMID>
  </reference>
  <reference>
    <citation>Wu FC, von Eckardstein A. Androgens and coronary artery disease. Endocr Rev. 2003 Apr;24(2):183-217. Review.</citation>
    <PMID>12700179</PMID>
  </reference>
  <reference>
    <citation>Keating NL, O'Malley AJ, Smith MR. Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer. J Clin Oncol. 2006 Sep 20;24(27):4448-56.</citation>
    <PMID>16983113</PMID>
  </reference>
  <reference>
    <citation>Smith MR. Changes in fat and lean body mass during androgen-deprivation therapy for prostate cancer. Urology. 2004 Apr;63(4):742-5.</citation>
    <PMID>15072892</PMID>
  </reference>
  <reference>
    <citation>Smith MR, Finkelstein JS, McGovern FJ, Zietman AL, Fallon MA, Schoenfeld DA, Kantoff PW. Changes in body composition during androgen deprivation therapy for prostate cancer. J Clin Endocrinol Metab. 2002 Feb;87(2):599-603.</citation>
    <PMID>11836291</PMID>
  </reference>
  <reference>
    <citation>Smith MR, Lee H, Nathan DM. Insulin sensitivity during combined androgen blockade for prostate cancer. J Clin Endocrinol Metab. 2006 Apr;91(4):1305-8. Epub 2006 Jan 24.</citation>
    <PMID>16434464</PMID>
  </reference>
  <reference>
    <citation>Braga-Basaria M, Dobs AS, Muller DC, Carducci MA, John M, Egan J, Basaria S. Metabolic syndrome in men with prostate cancer undergoing long-term androgen-deprivation therapy. J Clin Oncol. 2006 Aug 20;24(24):3979-83.</citation>
    <PMID>16921050</PMID>
  </reference>
  <reference>
    <citation>Werner N, Kosiol S, Schiegl T, Ahlers P, Walenta K, Link A, Böhm M, Nickenig G. Circulating endothelial progenitor cells and cardiovascular outcomes. N Engl J Med. 2005 Sep 8;353(10):999-1007.</citation>
    <PMID>16148285</PMID>
  </reference>
  <reference>
    <citation>Werner N, Junk S, Laufs U, Link A, Walenta K, Bohm M, Nickenig G. Intravenous transfusion of endothelial progenitor cells reduces neointima formation after vascular injury. Circ Res. 2003 Jul 25;93(2):e17-24. Epub 2003 Jun 26.</citation>
    <PMID>12829619</PMID>
  </reference>
  <reference>
    <citation>Vasa M, Fichtlscherer S, Aicher A, Adler K, Urbich C, Martin H, Zeiher AM, Dimmeler S. Number and migratory activity of circulating endothelial progenitor cells inversely correlate with risk factors for coronary artery disease. Circ Res. 2001 Jul 6;89(1):E1-7.</citation>
    <PMID>11440984</PMID>
  </reference>
  <reference>
    <citation>Dong C, Goldschmidt-Clermont PJ. Endothelial progenitor cells: a promising therapeutic alternative for cardiovascular disease. J Interv Cardiol. 2007 Apr;20(2):93-9. Review.</citation>
    <PMID>17391216</PMID>
  </reference>
  <reference>
    <citation>Foresta C, Caretta N, Lana A, De Toni L, Biagioli A, Ferlin A, Garolla A. Reduced number of circulating endothelial progenitor cells in hypogonadal men. J Clin Endocrinol Metab. 2006 Nov;91(11):4599-602. Epub 2006 Aug 22.</citation>
    <PMID>16926245</PMID>
  </reference>
  <reference>
    <citation>Foresta C, Zuccarello D, Biagioli A, De Toni L, Prana E, Nicoletti V, Ambrosini G, Ferlin A. Oestrogen stimulates endothelial progenitor cells via oestrogen receptor-alpha. Clin Endocrinol (Oxf). 2007 Oct;67(4):520-5. Epub 2007 Jun 15.</citation>
    <PMID>17573901</PMID>
  </reference>
  <reference>
    <citation>Foresta C, Zuccarello D, De Toni L, Garolla A, Caretta N, Ferlin A. Androgens stimulate endothelial progenitor cells through an androgen receptor-mediated pathway. Clin Endocrinol (Oxf). 2008 Feb;68(2):284-9. Epub 2007 Sep 4.</citation>
    <PMID>17803706</PMID>
  </reference>
  <reference>
    <citation>Iwakura A, Luedemann C, Shastry S, Hanley A, Kearney M, Aikawa R, Isner JM, Asahara T, Losordo DW. Estrogen-mediated, endothelial nitric oxide synthase-dependent mobilization of bone marrow-derived endothelial progenitor cells contributes to reendothelialization after arterial injury. Circulation. 2003 Dec 23;108(25):3115-21. Epub 2003 Dec 15.</citation>
    <PMID>14676142</PMID>
  </reference>
  <reference>
    <citation>Bergt C, Pennathur S, Fu X, Byun J, O'Brien K, McDonald TO, Singh P, Anantharamaiah GM, Chait A, Brunzell J, Geary RL, Oram JF, Heinecke JW. The myeloperoxidase product hypochlorous acid oxidizes HDL in the human artery wall and impairs ABCA1-dependent cholesterol transport. Proc Natl Acad Sci U S A. 2004 Aug 31;101(35):13032-7. Epub 2004 Aug 23.</citation>
    <PMID>15326314</PMID>
  </reference>
  <reference>
    <citation>Leder BZ, LeBlanc KM, Schoenfeld DA, Eastell R, Finkelstein JS. Differential effects of androgens and estrogens on bone turnover in normal men. J Clin Endocrinol Metab. 2003 Jan;88(1):204-10.</citation>
    <PMID>12519853</PMID>
  </reference>
  <reference>
    <citation>Mostaghel EA, Page ST, Lin DW, Fazli L, Coleman IM, True LD, Knudsen B, Hess DL, Nelson CC, Matsumoto AM, Bremner WJ, Gleave ME, Nelson PS. Intraprostatic androgens and androgen-regulated gene expression persist after testosterone suppression: therapeutic implications for castration-resistant prostate cancer. Cancer Res. 2007 May 15;67(10):5033-41.</citation>
    <PMID>17510436</PMID>
  </reference>
  <reference>
    <citation>Page ST, Lin DW, Mostaghel EA, Hess DL, True LD, Amory JK, Nelson PS, Matsumoto AM, Bremner WJ. Persistent intraprostatic androgen concentrations after medical castration in healthy men. J Clin Endocrinol Metab. 2006 Oct;91(10):3850-6. Epub 2006 Aug 1.</citation>
    <PMID>16882745</PMID>
  </reference>
  <reference>
    <citation>Page ST, Plymate SR, Bremner WJ, Matsumoto AM, Hess DL, Lin DW, Amory JK, Nelson PS, Wu JD. Effect of medical castration on CD4+ CD25+ T cells, CD8+ T cell IFN-gamma expression, and NK cells: a physiological role for testosterone and/or its metabolites. Am J Physiol Endocrinol Metab. 2006 May;290(5):E856-63. Epub 2005 Dec 13.</citation>
    <PMID>16352669</PMID>
  </reference>
  <reference>
    <citation>Herbst KL, Coviello AD, Page S, Amory JK, Anawalt BD, Bremner WJ. A single dose of the potent gonadotropin-releasing hormone antagonist acyline suppresses gonadotropins and testosterone for 2 weeks in healthy young men. J Clin Endocrinol Metab. 2004 Dec;89(12):5959-65.</citation>
    <PMID>15579744</PMID>
  </reference>
  <reference>
    <citation>Mauras N, Lima J, Patel D, Rini A, di Salle E, Kwok A, Lippe B. Pharmacokinetics and dose finding of a potent aromatase inhibitor, aromasin (exemestane), in young males. J Clin Endocrinol Metab. 2003 Dec;88(12):5951-6. Erratum in: J Clin Endocrinol Metab. 2004 Feb;89(2):732.</citation>
    <PMID>14671195</PMID>
  </reference>
  <reference>
    <citation>Lin EH, Hassan M, Li Y, Zhao H, Nooka A, Sorenson E, Xie K, Champlin R, Wu X, Li D. Elevated circulating endothelial progenitor marker CD133 messenger RNA levels predict colon cancer recurrence. Cancer. 2007 Aug 1;110(3):534-42.</citation>
    <PMID>17594720</PMID>
  </reference>
  <reference>
    <citation>Hill JM, Zalos G, Halcox JP, Schenke WH, Waclawiw MA, Quyyumi AA, Finkel T. Circulating endothelial progenitor cells, vascular function, and cardiovascular risk. N Engl J Med. 2003 Feb 13;348(7):593-600.</citation>
    <PMID>12584367</PMID>
  </reference>
  <reference>
    <citation>Gonzalo IT, Swerdloff RS, Nelson AL, Clevenger B, Garcia R, Berman N, Wang C. Levonorgestrel implants (Norplant II) for male contraception clinical trials: combination with transdermal and injectable testosterone. J Clin Endocrinol Metab. 2002 Aug;87(8):3562-72.</citation>
    <PMID>12161475</PMID>
  </reference>
  <results_reference>
    <citation>Rubinow KB, Snyder CN, Amory JK, Hoofnagle AN, Page ST. Acute testosterone deprivation reduces insulin sensitivity in men. Clin Endocrinol (Oxf). 2012 Feb;76(2):281-8. doi: 10.1111/j.1365-2265.2011.04189.x.</citation>
    <PMID>21797916</PMID>
  </results_reference>
  <results_reference>
    <citation>Rubinow KB, Tang C, Hoofnagle AN, Snyder CN, Amory JK, Heinecke JW, Page ST. Acute sex steroid withdrawal increases cholesterol efflux capacity and HDL-associated clusterin in men. Steroids. 2012 Apr;77(5):454-60. doi: 10.1016/j.steroids.2012.01.002. Epub 2012 Jan 15.</citation>
    <PMID>22266332</PMID>
  </results_reference>
  <verification_date>September 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 5, 2008</study_first_submitted>
  <study_first_submitted_qc>August 5, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 8, 2008</study_first_posted>
  <results_first_submitted>June 2, 2011</results_first_submitted>
  <results_first_submitted_qc>September 12, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">October 12, 2012</results_first_posted>
  <last_update_submitted>September 12, 2012</last_update_submitted>
  <last_update_submitted_qc>September 12, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 12, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Washington</investigator_affiliation>
    <investigator_full_name>Stephanie T. Page</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <keyword>HDL</keyword>
  <keyword>Insulin sensitivity</keyword>
  <keyword>testosterone</keyword>
  <keyword>estradiol</keyword>
  <keyword>cholesterol</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Testosterone</mesh_term>
    <mesh_term>Testosterone enanthate</mesh_term>
    <mesh_term>Testosterone undecanoate</mesh_term>
    <mesh_term>Testosterone 17 beta-cypionate</mesh_term>
    <mesh_term>Methyltestosterone</mesh_term>
    <mesh_term>Anastrozole</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Subjects were recruited using rosters from prior research studies, newspaper and online advertisements. Recruitment began December 2008 and ended March 2010.</recruitment_details>
      <pre_assignment_details>Before study procedures,2 withdrew consent and 1 was withdrawn by the investigator for missing appointments.4 failed inclusion criteria(1-anemia,1-low testosterone,1-high BMI,1-medications.
31 men enrolled. 22 men completed.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Group 1: Acyline + Placebo Gel, Placebo Pill</title>
          <description>Acyline 300 µg/kg injections Day 0 &amp; 14 + placebo (no active ingredients) transdermal gel daily for 28 days + oral placebo daily for 28 days</description>
        </group>
        <group group_id="P2">
          <title>Group 2: Acyline, Testosterone Gel, Placebo Pill</title>
          <description>Acyline 300 µg/kg injections Day 0 &amp; 14 + Testosterone gel (Testim) 10g 1% daily for 28 days + oral placebo daily for 28 days</description>
        </group>
        <group group_id="P3">
          <title>Group 3: Acyline, Testosterone Gel, Anastrazole Pill</title>
          <description>Acyline 300 μg/kg injections Day 0 &amp; 14 + 1% Testosterone gel 10g transdermal daily for 28 days + oral anastrozole 1 mg (Arimidex) daily for 28 days</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="8"/>
                <participants group_id="P3" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Group 1: Acyline + Placebo Gel, Placebo Pill</title>
          <description>Acyline 300 µg/kg injections Day 0 &amp; 14 + placebo (no active ingredients) transdermal gel daily for 28 days + oral placebo daily for 28 days</description>
        </group>
        <group group_id="B2">
          <title>Group 2: Acyline, Testosterone Gel, Placebo Pill</title>
          <description>Acyline 300 µg/kg injections Day 0 &amp; 14 + Testosterone gel (Testim) 10g 1% daily for 28 days + oral placebo daily for 28 days</description>
        </group>
        <group group_id="B3">
          <title>Group 3: Acyline, Testosterone Gel, Anastrazole Pill</title>
          <description>Acyline 300 μg/kg injections Day 0 &amp; 14 + 1% Testosterone gel 10g transdermal daily for 28 days + oral anastrozole 1 mg (Arimidex) daily for 28 days</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="8"/>
            <count group_id="B2" value="8"/>
            <count group_id="B3" value="8"/>
            <count group_id="B4" value="24"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="8"/>
                    <measurement group_id="B4" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="38.5" spread="10.6"/>
                    <measurement group_id="B2" value="24.3" spread="4.0"/>
                    <measurement group_id="B3" value="25.8" spread="8.4"/>
                    <measurement group_id="B4" value="30.0" spread="10.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="8"/>
                    <measurement group_id="B4" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Hispanic or Latino</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Not Hispanic or Latino</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="7"/>
                    <measurement group_id="B4" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown or Not Reported</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>American Indian or Alaska Native</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Native Hawaiian or Other Pacific Islander</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black or African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="7"/>
                    <measurement group_id="B4" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>More than one race</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown or Not Reported</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body Mass Index (BMI)</title>
          <units>kg/m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="26.2" spread="2.5"/>
                    <measurement group_id="B2" value="27.1" spread="3.8"/>
                    <measurement group_id="B3" value="23.7" spread="2.1"/>
                    <measurement group_id="B4" value="25.5" spread="3.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Endothelial Progenitor Cells</title>
        <description>Number of CD33 + CD134+ cells as a percentage of all lymphocytes</description>
        <time_frame>Baseline, Day 28</time_frame>
        <population>Statistical analyses were limited to changes from baseline within a given group and between-group comparisons were not performed</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1: Acyline + Placebo Gel + Placebo Pill</title>
            <description>Group 1: Acyline injections, transdermal placebo gel 10 g/day for 28 days, oral daily placebo pill for 28 days</description>
          </group>
          <group group_id="O2">
            <title>Group 2: Acyline + T-gel 10g/Day + Placebo Pill</title>
            <description>Acyline SQ inj. Day 0 &amp; 14 + T-gel and placebo pill for 28 days</description>
          </group>
          <group group_id="O3">
            <title>Group 3: Acyline + T-gel + Oral Anastrozole 1mg</title>
            <description>Acyline SQ inj. Day 0 &amp; 14 + T-gel and anastrozole for 28 days</description>
          </group>
        </group_list>
        <measure>
          <title>Endothelial Progenitor Cells</title>
          <description>Number of CD33 + CD134+ cells as a percentage of all lymphocytes</description>
          <population>Statistical analyses were limited to changes from baseline within a given group and between-group comparisons were not performed</population>
          <units>percentage of all lymphocytes</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.101" spread="0.032"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 28</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.081" spread="0.040"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>p value for the difference = 0.28</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.28</p_value>
            <method>paired t-test</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.02</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>0.0075</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.005</ci_lower_limit>
            <ci_upper_limit>0.035</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Follicle Stimulating Hormone (FSH)</title>
        <time_frame>Baseline, 28 days</time_frame>
        <population>Per protocol, the first 8 subjects were assigned to Group 1. Subsequent subjects were randomly assigned to Group 2 or Group 3.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1: Acyline + Placebo Gel, Placebo Pill</title>
            <description>Group 1: Acyline injections, transdermal placebo gel 10 g/day for 28 days, oral daily placebo pill for 28 days</description>
          </group>
          <group group_id="O2">
            <title>Group 2: Acyline, Testosterone Gel</title>
            <description>Group 2: Acyline injections, transdermal testosterone gel 10 g/day for 28 days, oral daily placebo pill for 28 days</description>
          </group>
          <group group_id="O3">
            <title>Group 3: Acyline, Testosterone Gel, Anastrazole Pill</title>
            <description>Arm 3: Acyline injections, transdermal testosterone gel 10 g/day for 28 days, oral daily anastrazole pill 1 mg for 28 days</description>
          </group>
        </group_list>
        <measure>
          <title>Follicle Stimulating Hormone (FSH)</title>
          <population>Per protocol, the first 8 subjects were assigned to Group 1. Subsequent subjects were randomly assigned to Group 2 or Group 3.</population>
          <units>IU/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.2" spread="2.4"/>
                    <measurement group_id="O2" value="2.9" spread="1.3"/>
                    <measurement group_id="O3" value="2.5" spread="0.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 28</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.42" spread="0.7"/>
                    <measurement group_id="O2" value="0.39" spread="0.5"/>
                    <measurement group_id="O3" value="0.87" spread="0.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Luteinizing Hormone Concentration (LH)</title>
        <time_frame>Baseline, Day 28</time_frame>
        <population>The analysis was per protocol. Following screening, the first 8 subjects were assigned to group I, and subsequent subjects enrolled were randomly assigned to either group 2 or 3.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1: Acyline + Placebo Gel, Placebo Pill</title>
            <description>Group 1: Acyline injections, transdermal placebo gel 10 g/day for 28 days, oral daily placebo pill for 28 days</description>
          </group>
          <group group_id="O2">
            <title>Group 2: Acyline, Testosterone Gel</title>
            <description>Group 2: Acyline injections, transdermal testosterone gel 10 g/day for 28 days, oral daily placebo pill for 28 days</description>
          </group>
          <group group_id="O3">
            <title>Group 3: Acyline, Testosterone Gel, Anastrozole</title>
            <description>Arm 3: Acyline injections, transdermal testosterone gel 10 g/day for 28 days, oral daily anastrozole pill 1 mg for 28 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Luteinizing Hormone Concentration (LH)</title>
          <population>The analysis was per protocol. Following screening, the first 8 subjects were assigned to group I, and subsequent subjects enrolled were randomly assigned to either group 2 or 3.</population>
          <units>IU/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.3" spread="2.3"/>
                    <measurement group_id="O2" value="4.7" spread="1.9"/>
                    <measurement group_id="O3" value="4.4" spread="2.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 28</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.31" spread="0.2"/>
                    <measurement group_id="O2" value="0.69" spread="1.2"/>
                    <measurement group_id="O3" value="1.55" spread="1.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Testosterone Concentration</title>
        <time_frame>Baseline, Day 28</time_frame>
        <population>Per protocol, the first 8 subjects were assigned to group I. Subsequent subjects were randomized to group 2 or group 3.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1: Acyline + Placebo Gel, Placebo Pill</title>
            <description>Group 1: Acyline injections, transdermal placebo gel 10 g/day for 28 days, oral daily placebo pill for 28 days</description>
          </group>
          <group group_id="O2">
            <title>Group 2: Acyline, Testosterone Gel</title>
            <description>Group 2: Acyline injections, transdermal testosterone gel 10 g/day for 28 days, oral daily placebo pill for 28 days</description>
          </group>
          <group group_id="O3">
            <title>Group 3: Acyline, Testosterone Gel, Anastrozole</title>
            <description>Group 3: Acyline injections, transdermal testosterone gel 10 g/day for 28 days, oral daily anastrozole pill 1 mg for 28 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Testosterone Concentration</title>
          <population>Per protocol, the first 8 subjects were assigned to group I. Subsequent subjects were randomized to group 2 or group 3.</population>
          <units>nmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline testosterone concentration</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.4" spread="3.4"/>
                    <measurement group_id="O2" value="16.3" spread="3.3"/>
                    <measurement group_id="O3" value="16.5" spread="2.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 28 testosterone concentration</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.8" spread="0.8"/>
                    <measurement group_id="O2" value="17.8" spread="5.5"/>
                    <measurement group_id="O3" value="19.0" spread="7.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Estradiol Concentration</title>
        <time_frame>Baseline, Day 28</time_frame>
        <population>Per protocol, the first 8 subjects were assigned to Group 1. Subsequent subjects were randomly assigned to Group 2 or Group 3.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1: Acyline + Placebo Gel, Placebo Pill</title>
            <description>Group 1: Acyline injections, transdermal placebo gel 10 g/day for 28 days, oral daily placebo pill for 28 days</description>
          </group>
          <group group_id="O2">
            <title>Group 2: Acyline, Testosterone Gel</title>
            <description>Group 2: Acyline injections, transdermal testosterone gel 10 g/day for 28 days, oral daily placebo pill for 28 days</description>
          </group>
          <group group_id="O3">
            <title>Group 3: Acyline, Testosterone Gel, Anastrozole Pill</title>
            <description>Group 3: Acyline injections, transdermal testosterone gel 10 g/day for 28 days, oral daily anastrozole pill 1 mg for 28 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Estradiol Concentration</title>
          <population>Per protocol, the first 8 subjects were assigned to Group 1. Subsequent subjects were randomly assigned to Group 2 or Group 3.</population>
          <units>pmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="95.4" spread="18.2"/>
                    <measurement group_id="O2" value="117.8" spread="28.6"/>
                    <measurement group_id="O3" value="96.3" spread="21.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 28</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31.9" spread="11.2"/>
                    <measurement group_id="O2" value="109.0" spread="28.8"/>
                    <measurement group_id="O3" value="36.5" spread="14.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Sex Hormone Binding Globulin (SHBG)</title>
        <time_frame>Baseline, Day 28</time_frame>
        <population>Per protocol, the first 8 subjects were assigned to Group I. Subsequent subjects were randomly assigned to Group 2 or Group 3.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1: Acyline + Placebo Gel, Placebo Pill</title>
            <description>Group 1: Acyline injections, transdermal placebo gel 10 g/day for 28 days, oral daily placebo pill for 28 days</description>
          </group>
          <group group_id="O2">
            <title>Group 2: Acyline, Testosterone Gel</title>
            <description>Group 2: Acyline injections, transdermal testosterone gel 10 g/day for 28 days, oral daily placebo pill for 28 days</description>
          </group>
          <group group_id="O3">
            <title>Group 3: Acyline, Testosterone Gel, Anastrozole Pill</title>
            <description>Group 3: Acyline injections, transdermal testosterone gel 10 g/day for 28 days, oral daily anastrozole pill 1 mg for 28 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Sex Hormone Binding Globulin (SHBG)</title>
          <population>Per protocol, the first 8 subjects were assigned to Group I. Subsequent subjects were randomly assigned to Group 2 or Group 3.</population>
          <units>nmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34.9" spread="17.1"/>
                    <measurement group_id="O2" value="23.0" spread="10.9"/>
                    <measurement group_id="O3" value="27.6" spread="6.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 28</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37.5" spread="16.4"/>
                    <measurement group_id="O2" value="22.1" spread="10.1"/>
                    <measurement group_id="O3" value="25.1" spread="4.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Quantitative Insulin Sensitivity Check Index (QUICKI)</title>
        <description>QUICKI is a measure of insulin sensitivity calculated using fasting insulin and glucose concentration in a participants blood. Higher QUICKI are associated with decreased insulin resistance and increased insulin sensitivity.</description>
        <time_frame>Baseline, Day 28, Day 56</time_frame>
        <population>per protocol</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1: Acyline + Placebo Gel, Placebo Pill</title>
            <description>Group 1: Acyline injections, transdermal placebo gel 10 g/day for 28 days, oral daily placebo pill for 28 days</description>
          </group>
          <group group_id="O2">
            <title>Group 2: Acyline, Testosterone Gel, Placebo Pill</title>
            <description>Group 2: Acyline injections, transdermal testosterone gel 10 g/day for 28 days, oral daily placebo pill for 28 days</description>
          </group>
          <group group_id="O3">
            <title>Group 3: Acyline, Testosterone Gel, Oral Anastrozole</title>
            <description>Group 3: Acyline injections, transdermal testosterone gel 10 g/day for 28 days, oral daily anastrozole pill 1 mg for 28 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Quantitative Insulin Sensitivity Check Index (QUICKI)</title>
          <description>QUICKI is a measure of insulin sensitivity calculated using fasting insulin and glucose concentration in a participants blood. Higher QUICKI are associated with decreased insulin resistance and increased insulin sensitivity.</description>
          <population>per protocol</population>
          <units>QUICKI index</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.36" spread="0.03"/>
                    <measurement group_id="O2" value="0.35" spread="0.02"/>
                    <measurement group_id="O3" value="0.36" spread="0.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 28</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.34" spread="0.03"/>
                    <measurement group_id="O2" value="0.35" spread="0.02"/>
                    <measurement group_id="O3" value="0.38" spread="0.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 56</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.35" spread="0.03"/>
                    <measurement group_id="O2" value="0.35" spread="0.02"/>
                    <measurement group_id="O3" value="0.36" spread="0.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Homeostasis Model of Insulin Resistance (HOMA-IR)</title>
        <description>HOMA IR is a measure of insulin sensitivity calculated using fasting insulin and glucose concentration in a participants blood. Higher HOMA IR numbers are associated with increased insulin resistance and decreased insulin sensitivity.</description>
        <time_frame>Baseline, Day 28, Day 56</time_frame>
        <population>per protocol</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1: Acyline + Placebo Gel, Placebo Pill</title>
            <description>Group 1: Acyline injections, transdermal placebo gel 10 g/day for 28 days, oral daily placebo pill for 28 days</description>
          </group>
          <group group_id="O2">
            <title>Group 2: Acyline, Testosterone Gel, Placebo Pill</title>
            <description>Group 2: Acyline injections, transdermal testosterone gel 10 g/day for 28 days, oral daily placebo pill for 28 days</description>
          </group>
          <group group_id="O3">
            <title>Group 3: Acyline, Testosterone Gel, Oral Anastrozole</title>
            <description>Group 3: Acyline injections, transdermal testosterone gel 10 g/day for 28 days, oral daily anastrozole pill 1 mg for 28 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Homeostasis Model of Insulin Resistance (HOMA-IR)</title>
          <description>HOMA IR is a measure of insulin sensitivity calculated using fasting insulin and glucose concentration in a participants blood. Higher HOMA IR numbers are associated with increased insulin resistance and decreased insulin sensitivity.</description>
          <population>per protocol</population>
          <units>HOMA score</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.8" spread="0.9"/>
                    <measurement group_id="O2" value="2.0" spread="0.9"/>
                    <measurement group_id="O3" value="1.6" spread="0.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 28</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.4" spread="1.0"/>
                    <measurement group_id="O2" value="1.9" spread="0.9"/>
                    <measurement group_id="O3" value="1.4" spread="0.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 56</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.2" spread="0.9"/>
                    <measurement group_id="O2" value="1.9" spread="0.9"/>
                    <measurement group_id="O3" value="1.7" spread="0.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Fasting Serum Insulin</title>
        <time_frame>Baseline, Day 28, Day 56</time_frame>
        <population>per protocol</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1: Acyline + Placebo Gel, Placebo Pill</title>
            <description>Group 1: Acyline injections, transdermal placebo gel 10 g/day for 28 days, oral daily placebo pill for 28 days</description>
          </group>
          <group group_id="O2">
            <title>Group 2: Acyline, Testosterone Gel, Placebo Pill</title>
            <description>Group 2: Acyline injections, transdermal testosterone gel 10 g/day for 28 days, oral daily placebo pill for 28 days</description>
          </group>
          <group group_id="O3">
            <title>Group 3: Acyline, Testosterone Gel, Oral Anastrozole</title>
            <description>Group 3: Acyline injections, transdermal testosterone gel 10 g/day for 28 days, oral daily anastrozole pill 1 mg for 28 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Fasting Serum Insulin</title>
          <population>per protocol</population>
          <units>picomolar</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="54" spread="26"/>
                    <measurement group_id="O2" value="65" spread="28"/>
                    <measurement group_id="O3" value="50" spread="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 28</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="69" spread="25"/>
                    <measurement group_id="O2" value="59" spread="26"/>
                    <measurement group_id="O3" value="42" spread="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 56</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="54" spread="26"/>
                    <measurement group_id="O2" value="64" spread="27"/>
                    <measurement group_id="O3" value="50" spread="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Fasting Lipid Levels</title>
        <time_frame>Baseline, Day 28, Day 56</time_frame>
        <population>per protocol</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1: Acyline + Placebo Gel, Placebo Pill</title>
            <description>Group 1: Acyline injections, transdermal placebo gel 10 g/day for 28 days, oral daily placebo pill for 28 days</description>
          </group>
          <group group_id="O2">
            <title>Group 2: Acyline, Testosterone Gel, Placebo Pill</title>
            <description>Group 2: Acyline injections, transdermal testosterone gel 10 g/day for 28 days, oral daily placebo pill for 28 days</description>
          </group>
          <group group_id="O3">
            <title>Group 3: Acyline, Testosterone Gel, Oral Anastrozole</title>
            <description>Group 3: Acyline injections, transdermal testosterone gel 10 g/day for 28 days, oral daily anastrozole pill 1 mg for 28 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Fasting Lipid Levels</title>
          <population>per protocol</population>
          <units>mmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Total cholesterol Day 0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.97" spread="1.1"/>
                    <measurement group_id="O2" value="4.48" spread="0.4"/>
                    <measurement group_id="O3" value="4.56" spread="1.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total cholesterol Day 28</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.44" spread="1.2"/>
                    <measurement group_id="O2" value="4.51" spread="0.3"/>
                    <measurement group_id="O3" value="4.56" spread="0.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total cholesterol Day 56</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.95" spread="1.1"/>
                    <measurement group_id="O2" value="4.14" spread="0.6"/>
                    <measurement group_id="O3" value="4.27" spread="1.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>LDL choesterol Day 0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.95" spread="0.8"/>
                    <measurement group_id="O2" value="2.77" spread="0.3"/>
                    <measurement group_id="O3" value="2.67" spread="1.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>LDL cholesterol Day 28</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.29" spread="0.7"/>
                    <measurement group_id="O2" value="2.80" spread="0.2"/>
                    <measurement group_id="O3" value="2.75" spread="0.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>LDL cholesterol Day 56</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.87" spread="0.5"/>
                    <measurement group_id="O2" value="2.49" spread="0.5"/>
                    <measurement group_id="O3" value="2.51" spread="1.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HDL cholesterol Day 0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.19" spread="0.2"/>
                    <measurement group_id="O2" value="1.32" spread="0.2"/>
                    <measurement group_id="O3" value="1.40" spread="0.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HDL cholesterol Day 28</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.37" spread="0.2"/>
                    <measurement group_id="O2" value="1.32" spread="0.1"/>
                    <measurement group_id="O3" value="1.32" spread="0.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HDL cholesterol Day 56</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.19" spread="0.2"/>
                    <measurement group_id="O2" value="1.32" spread="0.2"/>
                    <measurement group_id="O3" value="1.30" spread="0.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Triglycerides Day 0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.79" spread="2.1"/>
                    <measurement group_id="O2" value="0.82" spread="0.2"/>
                    <measurement group_id="O3" value="1.08" spread="0.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Triglycerides Day 28</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.73" spread="1.4"/>
                    <measurement group_id="O2" value="0.86" spread="0.3"/>
                    <measurement group_id="O3" value="1.08" spread="0.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Triglycerides Day 56</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.89" spread="2.3"/>
                    <measurement group_id="O2" value="0.80" spread="0.4"/>
                    <measurement group_id="O3" value="1.02" spread="0.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Dec 2008 - May 2010</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Group 1: Acyline + Placebo Gel, Placebo Pill</title>
          <description>Acyline 300 µg/kg injections Day 0 &amp; 14 + placebo (no active ingredients) transdermal gel daily for 28 days + oral placebo daily for 28 days</description>
        </group>
        <group group_id="E2">
          <title>Group 2: Acyline, Testosterone Gel, Placebo Pill</title>
          <description>Acyline 300 µg/kg injections Day 0 &amp; 14 + Testosterone gel (Testim) 10g 1% daily for 28 days + oral placebo daily for 28 days</description>
        </group>
        <group group_id="E3">
          <title>Group 3: Acyline, Testosterone Gel, Anastrazole Pill</title>
          <description>Acyline 300 μg/kg injections Day 0 &amp; 14 + 1% Testosterone gel 10g transdermal daily for 28 days + oral anastrozole 1 mg (Arimidex) daily for 28 days</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>emotional lability, irritability</sub_title>
                <description>This is expected in group 1 subjects (hypogonadal). The group 3 subject with emotional lability also reported skin irritation at the testosterone gel site.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>fatigue</sub_title>
                <description>Fatigue is anticipated and consistent with hypogonadal symptoms for Group 1 (placebo gel. The group 2 subject also reported studying late and spending the night in the library during midterm week. Fatigue is described in the consent as a possibility.</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="8"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>hot flashes</sub_title>
                <description>Hot flashes are anticipated and consistent with hypogonadal symptoms for Group 1 (placebo gel). This is described in the consent.</description>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>lightheadedness, clammy</sub_title>
                <description>Mild symptoms occurred two days and were deemed possibly related to the drug. No action or medications were required in this group I (hypogonadal symptoms expected) subject.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>low libido</sub_title>
                <description>Low libido is anticipated and consistent with hypogonadal symptoms for Group 1 (placebo gel). This is described in the consent.</description>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>itching at acyline site</sub_title>
                <description>The written consent describes itchiness at the site in most men. One (group 2)is not counted here, but is described in &quot;participant flow&quot;. Symptoms had resolved on Day 14 but he withdrew consent before the second acyline injection.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>skin irritation, gel application site</sub_title>
                <description>One(group 1) complaint of itchiness;one(group 3) complaint of dry skin at testosterone gel application site. Both subjects were instructed to apply elsewhere; complaints were resolved with no further symptoms at old and new application sites.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>itching rash</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Stephanie T. Page, MD, PhD</name_or_title>
      <organization>University of Washington</organization>
      <phone>206-616-0483</phone>
      <email>page@u.washington.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

